GlassScriptPhysician profile
Waheed S Ibrahimi
NPI 1174716583
$5,503.11
in general payments reported to CMS, 2019-2025
39 companies · $3,159 in 2025
The $3,159 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $855 · 2024: $1,488 · 2025: $3,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,503.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,026.05 | 2023-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $574.72 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Sk Life Science, INC. | $512.36 | 2023-2025 | |
| Abbvie INC. | $398.02 | 2023-2025 | |
| Lilly USA, LLC | $339.76 | 2023-2025 | Amyvid, Mounjaro, Emgality |
| Otsuka America Pharmaceutical, INC. | $314.26 | 2023-2025 | Rexulti, Nuedexta |
| Csl Behring | $250.65 | 2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $236.69 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Aucta Pharmaceuticals, INC. | $178.37 | 2024-2025 | Motpoly Xr |
| Pfizer INC. | $167.75 | 2024-2025 | |
| Acorda Therapeutics, INC | $151.95 | 2023-2024 | Ampyra, Inbrija |
| Ge Healthcare | $113.61 | 2024-2025 | |
| Tanabe Pharma America, INC. | $104.28 | 2023-2025 | Radicava |
| Sumitomo Pharma America, INC. | $98.52 | 2023-2024 | Aptiom |
| Indivior INC. | $91.35 | 2024-2025 | Sublocade |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $90.74 | 2023-2024 | Panzyga |
| Biogen, INC. | $77.87 | 2023-2025 | Tysabri, Vumerity, Zurzuvae |
| Merz Pharmaceuticals, LLC | $66.39 | 2025 | Ampyra, Inbrija |
| Axsome Therapeutics, INC. | $65.59 | 2025 | Symbravo |
| Lundbeck LLC | $64.03 | 2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $61.00 | 2025 | |
| Scilex Pharmaceuticals INC. | $60.06 | 2023 | Ztlido, Elyxyb |
| Currax Pharmaceuticals LLC | $52.57 | 2023 | Onzetra Xsail, Nexletol, Nexlizet |
| Celgene Corporation | $45.39 | 2025 | Zeposia |
| Novo Nordisk INC | $36.85 | 2025 | Wegovy, Ozempic |
| Ipsen Biopharmaceuticals, INC | $31.77 | 2023 | Dysport |
| Exact Sciences Corporation | $28.87 | 2025 | The Cologuard Plus Collection Kit |
| Tris Pharma INC | $26.68 | 2024 | Dyanavel Xr |
| Averitas Pharma INC. | $24.72 | 2024 | Qutenza |
| Eisai INC. | $24.69 | 2024 | |
| Insulet Corporation | $24.60 | 2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $24.49 | 2023 | Rytary |
| Globus Medical, INC. | $23.14 | 2025 | Senza |
| Alkermes, INC. | $23.06 | 2025 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $22.01 | 2025 | Shingrix |
| Bausch Health US, LLC | $20.47 | 2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $18.88 | 2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $16.57 | 2023 | Quviviq |
| Phadia US INC. | $14.33 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waheed Ibrahimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.